Novel Dual-Reporter Preclinical Screen for Antiastrocytoma Agents Identifies Cytostatic and Cytotoxic Compounds

Mouse Cancer Genetics Program, National Cancer Institute, Frederick, Maryland 21702, USA.
Journal of Biomolecular Screening (Impact Factor: 2.42). 08/2008; 13(8):795-803. DOI: 10.1177/1087057108321085
Source: PubMed


Astrocytoma/glioblastoma is the most common malignant form of brain cancer and is often unresponsive to current pharmacological therapies and surgical interventions. Despite several potential therapeutic agents against astrocytoma and glioblastoma, there are currently no effective therapies for astrocytoma, creating a great need for the identification of effective antitumor agents. The authors have developed a novel dual-reporter system in Trp53/Nf1-null astrocytoma cells to simultaneously and rapidly assay cell viability and cell cycle progression as evidenced by activity of the human E2F1 promoter in vitro. The dual-reporter high-throughput assay was used to screen experimental therapeutics for activity in Trp53/Nf1-null astrocytoma. Several compounds were identified demonstrating selectivity for astrocytoma over primary astrocytes. The dual-reporter system described here may be a valuable tool for identifying potential antitumor treatments that specifically target astrocytoma.

Download full-text


Available from: Karlyne M Reilly,
  • Source
    • "After attachment (!4 h), extracts, fractions, or pure compounds were added and red and green luminescence assessed using Promega ChromoGlo reagent 2 d later. Inhibition of the green luminescence signal (E2F1) reflects growth inhibition while inhibition of the red signal (CMV) indicates loss of cell viability (Hawes et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A neurofibromatosis type 1 (NF1) based bioassay-guided phytochemical investigation on Simarouba berteroana led to the isolation of one new canthin-6-one-9-methoxy-5-O-β-d-glucopyranoside (1), seven known canthine alkaloids (2–8), two known quassinoids (9–10) and a known neo-lignan (11). The structures of all compounds were established by HRMS, 1D- and 2D NMR analysis and comparison with previously reported data. Most of the compounds inhibited the proliferation of an Nf1- and p53-deficient mouse glioma cell line at non-cytotoxic concentrations.
    Phytochemistry Letters 02/2014; 7(1):42–45. DOI:10.1016/j.phytol.2013.09.007 · 1.45 Impact Factor
  • Source
    • "Owing to simultaneous detection of two different reporters, this system is able to distinguish cytotoxic compounds from cytostatic compounds in a single assay. This system can also be used to examine the pharmacology of antitumor agents and combinatorial treatments in a high-throughput manner in Nf1- null;Trp53-null astrocytoma cells, and then positive hits can be screened against a wider range of human and mouse astrocytoma cell lines (Hawes et al. 2008) and in vivo systems. The G/R-luc dual-reporter system will likely be a valuable tool in the identification and characterization of potential antitumor agents specifically targeting astrocytoma and Nf1-null;Trp53- null tumors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurofibomatosis (NF1) patients are susceptible to multiple tumors of the nervous system including neurofibromas, optic glioma, malignant peripheral nerve sheath tumors (MPNSTs), and astrocytoma. The Nf1+/-;Trp53+/- (NPcis) mouse model of NF1 spontaneously develops astrocytoma and MPNSTs that are very similar to human NF1 tumors. To use this model for testing potential therapeutics, we have developed systems that take advantage of bioluminescent reporters of tumor growth. We have generated E2F1 promoter-driving luciferase (ELUX) reporter mice to detect proliferating tumors in NPcis mice in vivo using bioluminescence. The power of this system is that it enables looking at tumor evolution and detecting spontaneous tumors at early stages of development as they evolve within their natural haploinsufficient microenvironment. This system can be used to identify tumors at different stages of tumorigenesis and to examine where spontaneous NF1 tumors initiate. The ability to rapidly screen multiple animals at a time increases the potential for use of this model in preclinical trials. This model will be valuable for the characterization of spontaneous NF1 tumors and will be important for studying the treatment and prevention of NF1 tumors in vivo.
    Toxicologic Pathology 02/2010; 38(1):123-30. DOI:10.1177/0192623309357075 · 2.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Astrocytic gliomas are the most common primary brain tumors. They include diffuse astrocytomas, mixed oligoastrocytoma, anaplastic astrocytomas, and a subset of glioblastoma multiforme (GBM). Studies on human GBM have shown that upregulation of the Ras signaling pathway and disruption of the p53 checkpoint pathway are central to the formation of these tumors. Although much is now known about the molecular pathways altered in these tumors, they remain largely incurable, primarily due to their diffuse infiltration of the brain and lack of response to chemotherapeutics. The Nf1–/+; Trp53–/+cis mouse model develops diffuse anaplastic astrocytoma and GBM with histology that closely resembles the tumors seen in patients. The incidence of astrocytic gliomas varies in the model depending on the inheritance of mutations from the mother or father and on genetic background. Males and females show different effects, suggesting that sex influences the genetic and epigenetic factors that determine the susceptibility of an individual animal to astrocytic gliomas. This model system, including both genetically engineered mice and derivative cell lines, is useful for understanding the basic biological mechanisms underlying the formation of astrocytic gliomas and for preclinical testing of experimental therapeutics.
    12/2008: pages 93-118;
Show more